VivoSeq
Other

IRIS

0

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

IRIS is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

40/100

Attrition Rate

60/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Terminated3 · 60%
Completed2 · 40%

Clinical Trials

Trial Activity

Performance of Rigid Gas Permeable (RGP) Scleral Contact Lenses With a Passive Artificial Iris
Terminated·UUniversity Ghent·N/A·NCT04040790·10 enrolled
Comparison of Different Up-dosing Schedules With Osiris
Terminated·AALK-Abelló A/S·Phase 2·NCT01240954·210 enrolled
Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride
Completed·—·N/A·NCT03917940·70 enrolled
Study of TRAVATAN in Subjects With Iris Pigmentation Changes
Terminated·AAlcon Research·N/A·NCT00047554·336 enrolled
Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense
Completed·AALK-Abelló A/S·Phase 2·NCT01425788·236 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)